Impact of fremanezumab on headache intensity and duration of remaining migraine attacks: PEARL 3rd interim analysis

被引：0
|
作者：
Tassorelli, C. [1 ,2 ]
Mitsikostas, D. [3 ]
Amin, F. [4 ,5 ]
Kokturk, P. [6 ]
Schankin, C. [7 ]
Sahin, G. [8 ]
Pozo-Rosich, P. [9 ,10 ]
Dorman, P. [11 ]
Nezadal, T. [12 ]
Poole, A. [13 ]
Martins, I. [14 ]
Sumelahti, M. [15 ]
Krasenbaum, L. [16 ]
Ahn, A.
Akcicek, H. [6 ]
Ashina, M. [17 ,18 ]
机构：
[1] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy
[2] IRCCS Mondino Fdn, Pavia, Italy
[3] Natl & Kapodistrian Univ Athens, Aeginit Hosp, Dept Neurol 1, Athens, Greece
[4] Copenhagen Univ Hosp Rigshosp Glostrup, Dept Neurol, Danish Headache Ctr, Copenhagen, Denmark
[5] Univ Copenhagen, Dept Neurorehabilitat Traumat Brain Injury, Rigshosp Glostrup, Copenhagen, Denmark
[6] Teva Netherlands BV, Amsterdam, Netherlands
[7] Univ Bern, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland
[8] Lund Univ, Dept Clin Sci Lund, Skaneuro Neurol Clin, Lund, Sweden
[9] Univ Autonoma Barcelona, Headache Unit, Barcelona, Spain
[10] Univ Autonoma Barcelona, Vall dHebron Hosp & Res Inst, Res Grp, Barcelona, Spain
[11] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle, England
[12] Charles Univ Prague, Inst Neuropsychiat Care, Sch Med 1, Prague, Czech Republic
[13] Oslo Headache Ctr, Oslo, Norway
[14] Univ Lisbon, Ctr Estudos Egas Moniz, Fac Med, Lisbon, Portugal
[15] Univ Tampere, Fac Med & Hlth Technol, Tampere, Finland
[16] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA
[17] Copenhagen Univ Hosp Rigshosp Glostrup, Danish Headache Ctr, Dept Neurol, Copenhagen, Denmark
[18] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO-583
引用
收藏
页码：690 / 690
页数：1
相关论文
共 50 条
  • [41] Efficacy and Tolerability of Certolizumab pegol for the Treatment of rheumatoid Arthritis in clinical Practice in Germany: 3rd Interim Analysis of non-interventional Study "Fast"
    Burmester, G.
    Mueller-Ladner, U.
    Nuesslein, H.
    von Hinueber, U.
    Edelmann, E.
    Detert, J.
    Hoehle, M.
    Richter, C.
    Klopsch, T.
    Kumke, T.
    Fricke, D.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 100 - 100
  • [42] Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab plus ipilimumab plus /- chemotherapy for metastatic NSCLC
    Azuma, K.
    Imai, H.
    Yamaguchi, T.
    Kijima, T.
    Kishi, K.
    Fujita, K.
    Saito, H.
    Shiraishi, Y.
    Tanizaki, J.
    Takashima, Y.
    Tambo, Y.
    Watanabe, S.
    Hataji, O.
    Toi, Y.
    Fukuhara, T.
    Ohsugi, T.
    Kuroda, H.
    Ohe, Y.
    Horinouchi, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1328 - S1328
  • [43] Effects of omega-3 fatty acids on the frequency, severity, and duration of migraine attacks: A systematic review and meta-analysis of randomized controlled trials
    Maghsoumi-Norouzabad, Leila
    Mansoori, Anahita
    Abed, Reza
    Shishehbor, Farideh
    NUTRITIONAL NEUROSCIENCE, 2018, 21 (09) : 614 - 623
  • [44] Impact of Fremanezumab on Headache-related Disability in Patients With Migraine and Inadequate Response to 2-4 Classes of Preventive Medication: Results of the Open-Label Extension of the Phase 3b FOCUS Study
    Starling, A. J.
    Ramirez-Campos, V
    Ning, X.
    Cohen, J. M.
    Yang, R.
    Brandes, J.
    HEADACHE, 2020, 60 : 18 - 19
  • [45] Previous Therapy Strategy Impact on Efficiency of Anlotinib Hydrochloride as 3rd Line Treatment: A Subgroup Analysis of ALTER0303 Trial
    Yang, S.
    Wang, L.
    Wang, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S576 - S576
  • [46] ANALYSIS OF STRESS INTENSITY FACTORS FOR SURFACE CRACKS SUBJECTED TO ARBITRARILY DISTRIBUTED SURFACE STRESSES (3RD REPORT, ANALYSIS AND APPLICATION OF INFLUENCE COEFFICIENTS FOR ROUND BARS WITH A SEMIELLIPTICAL SURFACE CRACK).
    Shiratori, Masaki
    Miyoshi, Toshiro
    Sakai, Yoshiaki
    Zhang, Guang rong
    Nippon Kikai Gakkai Ronbunshu, A Hen/Transactions of the Japan Society of Mechanical Engineers, Part A, 1987, 53 (488): : 779 - 785
  • [47] BUDGET IMPACT ANALYSIS OF PANOBINOSTAT - BORTEZOMIB AND DEXAMETHASONE, AS 3RD OR 4TH LINE OF TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN GREECE
    Vellopoulou, K.
    Kourlaba, G.
    Delimpasi, S.
    Chatzikou, M.
    Katodritou, E.
    Konstantopoulou, K.
    Megalakaki, K.
    Pouli, A.
    Repousis, P.
    Terpos, E.
    VALUE IN HEALTH, 2016, 19 (07) : A729 - A729
  • [48] Results of the 3rd interim analysis of the non-interventional MOMENT II-study for determining efficacy and safety of Nilotinib in newly diagnosed Ph plus CML patients in chronic phase
    Lathan, B.
    Sauer, A.
    Ulshoefer, T.
    Lange, E.
    Tebbe, S.
    Schulze, M.
    Janssen, J.
    Meincke, M.
    Frank, O.
    Tesch, H.
    Oncology Research and Treatment, 2015, 38 : 134 - 135
  • [49] Breath Powered™ Nasal Delivery of Sumatriptan Powder (AVP-825): An Exploratory Analysis of Response in Migraine Patients Grouped by Baseline Headache Intensity from the Phase 3 TARGET Study
    Cady, R. K.
    McAllister, P.
    Spierings, E. L.
    Messina, J.
    Carothers, J.
    Djupesland, P. G.
    Mahmoud, R. A.
    HEADACHE, 2014, 54 : 33 - 33
  • [50] Analysis of everolimus starting dose as prognostic marker in HR plus mBC patients treated with everolimus (EVE) plus exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO.
    Fasching, Peter A.
    Grischke, Eva -Maria
    Schuetz, Florian
    Decker, Thomas
    Uleer, Christoph
    Salat, Christoph
    Foerster, Frank
    Schmidt, Marcus
    Mundhenke, Christoph
    Tesch, Hans
    Jackisch, Christian
    Wimberger, Pauline
    Aktas, Bahriye
    Zahn, Mark -Oliver
    Tome, Oliver
    Bloch, Wilhelm
    Hanson, Sven
    Fischer, Thomas
    Schubert, Joerg
    Lueftner, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345